News and Press Releases
Kite Presents New Data for Yescarta (axicabtagene ciloleucel) CAR T-cell Therapy Highlighting Manufacturing Excellence and Cost-Effectiveness in the US
Data Highlights Industry-leading Manufacturing Success Rates for US Axicabtagene Ciloleucel Patients from Launch to Present Data Also Supports Cost-effectiveness of Axicabtagene Ciloleucel Versus Bispecific Antibodies 16 February 2024 – Stockley...
Category: BioManufacturing
Posted: February 21, 2024
Real-World Evidence Demonstrates Feasibility and Safety of Outpatient Administration of Yescarta (axicabtagene ciloleucel)
Findings show comparable safety for patients administered axicabtagene ciloleucel in the outpatient setting in the US to inpatient infusion Real-world evidence supports further exploration of use of outpatient administration of...
Category: Clinical Trials
Posted: February 15, 2024
Gilead Sciences Strengthens Commitment to Inflammatory Disease with New Research Centre
14 February 2024 -- Oxford, UK -- On 14 February, Gilead Sciences held a ribbon-cutting event to celebrate the opening of its new research site at the Business Park in...
Category: BioManufacturing
Posted: February 14, 2024
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers
At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world...
Category: Clinical Trials
Posted: December 12, 2023
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...
Category: Clinical Trials
Posted: October 24, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Kite’s CAR T-Cell Therapy YESCARTA (Axicabtagene Ciloleucel) Compared with Bispecifics in R/R DLBCL in Two Analyses at ESMO 2023
23 October 2023 -- Stockley Park, UK -- Kite, a Gilead Company, today announced results from two indirect comparative analyses of its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) versus bispecific...
Category: Clinical Trials
Posted: October 23, 2023
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma · First Significant Improvement in Overall Survival in Two Decades...
Category: Pharmaceutical
Posted: October 23, 2023
Gilead and Kite Oncology Present Important Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy (sacituzumab govitecan-hziy) in Metastatic Breast Cancers – New Data Demonstrate Potential of Sacituzumab Govitecan in Small Cell Lung...
Category: Pharmaceutical
Posted: October 16, 2023
Kite’s CAR T-Cell Therapy Accepted for Use on the NHS in Scotland to Treat Aggressive Form of Blood Cancer
First CAR T-cell therapy for adult (26+) patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) reimbursed in Scotland 9 October 2023 -- London, UK -- Gilead Sciences...
Category: Pharmaceutical
Posted: October 9, 2023
MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland
Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...
Category: Pharmaceutical
Posted: October 9, 2023
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
